Gsk Plc ADR (GSK) Stock Price, Quote & News

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 44 20 8047 5000

Website: www.gsk.com

Address:

79 New Oxford Street, London, United Kingdom

Ro_Patel Feb. 3 at 10:44 PM

Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE

0 · Reply

Investor6 Jan. 30 at 4:21 PM

$JNJ Johnson & Johnson announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed an additional indication for its prostate cancer therapy Akeega, marketed with $GSK (GSK).

0 · Reply

JuggernautRaider Jan. 30 at 1:14 PM

$TNXP Vertex presented at the same summit for their non-opioid analgesic. If the launch goes well, $VRTX could be one of the buyers - or someone else that needs a strong CNS product & pipeline like $GSK or $PFE ? Also wonder if Vertex is the ideal ex-US partner. Tonix can handle the US launch but Europe, Japan, China, and the other regions are a different beast 🐂

0 · Reply

oceanviewhi Jan. 30 at 12:45 AM

$IBRX In January 2026, GlaxoSmithKline (GSK) has emerged as a key player in the "Immunotherapy 2.0" landscape. While Dr. Pat has been critiquing the mRNA giants like Pfizer, he is positioning $IBRX's ANKTIVA as a complementary force to GSK’s advanced oncology and immunology assets. Here are the key updates regarding Glaxo ($GSK) and ImmunityBio ($IBRX): • The Jemperli "Rescue" Strategy: GSK’s blockbuster anti-PD-1, Jemperli (dostarlimab), is a leader in endometrial and rectal cancers. Dr. Pat’s recent data (Jan 2026) suggests that ANKTIVA can "rescue" patients who have failed PD-1 therapies. There is high speculation that $IBRX is targeting a combo with Jemperli to overcome the "immune exhaustion" seen in late-stage uterine and lung cancer patients.

1 · Reply

BillionerOfKing Jan. 29 at 6:18 PM

$GSK Current Stock Price: $50.87 Contracts to trade: $50 GSK Jan 30 2026 Call Entry: $0.70 Exit: $1.25 ROI: 79% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Alex19949 Jan. 29 at 5:06 PM

$GSK Low volatility environment

0 · Reply

Stock_Savage Jan. 28 at 3:07 PM

$PFE Took my profits from $GSK and added to my $PFE position

0 · Reply

Coyote_7 Jan. 27 at 10:10 PM

$CYDY $MRK $GSK $RHHBY ICIs treat cancers and can now be combined with Leronlimab. Longs, our time is coming!! 🔥 Prime-and-Pair Agent to unlock market share for years to come!! "These Leronlimab early-phase clinical trials were started pre-pandemic, when immune checkpoint inhibitors (“ICIs”) were still an emerging option in advanced triple-negative breast cancer,” said Dr. Milana V. Dolezal. “In this pooled analysis, we see sustained clinical benefit over five years later,..."

0 · Reply

Justrise07 Jan. 27 at 6:34 PM

$GSK are you buying $CAMP therapudics , what’s going on ?

0 · Reply

taxplanr Jan. 25 at 9:55 PM

8000 is a lot of cancer patients starting from zero and less tha a year $BNTX $MRNA $BMY $GSK will there be anyone left? https://makisw.substack.com/p/breaking-news-we-now-have-over-8000?utm_source=post-email-title&publication_id=1385328&post_id=185569818&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

WVE

Jan 30, 2026, 3:00 AM EST - 4 days ago

Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK

SHEL VOD

Jan 21, 2026, 10:00 AM EST - 13 days ago

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Jan 20, 2026, 2:13 PM EST - 14 days ago

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

RAPT

Jan 20, 2026, 9:00 AM EST - 14 days ago

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Jan 20, 2026, 7:20 AM EST - 14 days ago

GSK to buy food allergy drug maker RAPT in $2.2bn deal

RAPT

Jan 20, 2026, 5:07 AM EST - 14 days ago

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

Jan 20, 2026, 2:55 AM EST - 14 days ago

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

Jan 20, 2026, 2:48 AM EST - 14 days ago

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

Jan 20, 2026, 2:11 AM EST - 14 days ago

GSK to buy RAPT Therapeutics for $2.2 billion

RAPT

Jan 16, 2026, 8:40 AM EST - 18 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS MRK

Jan 13, 2026, 2:46 PM EST - 21 days ago

GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 22 days ago

GSK Still Has Room To Run Despite Vaccine Cyclicality

Jan 12, 2026, 6:15 AM EST - 22 days ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

SMMT

Jan 8, 2026, 7:09 PM EST - 25 days ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

ANAB

Jan 8, 2026, 9:00 AM EST - 26 days ago

GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development

Jan 7, 2026, 11:48 AM EST - 27 days ago

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

IONS

Jan 7, 2026, 2:09 AM EST - 27 days ago

GSK's chronic hepatitis B treatment meets main goal in key studies

Dec 31, 2025, 6:08 AM EST - 4 weeks ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

LLY NVS PFE SNY

Dec 21, 2025, 5:56 PM EST - 6 weeks ago

Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln

Dec 21, 2025, 5:43 PM EST - 6 weeks ago

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY MRK AMGN GILD NVS SNY

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD MRK NVS SNY

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD MRK NVS SNY

Dec 18, 2025, 4:25 PM EST - 6 weeks ago

GSK: 2026 Looks Good

Dec 16, 2025, 9:55 PM EST - 6 weeks ago

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Dec 16, 2025, 6:10 PM EST - 6 weeks ago

US FDA approves GSK's twice-yearly asthma drug

Dec 15, 2025, 12:02 PM EST - 7 weeks ago

UK approves GSK's twice-yearly asthma drug

Dec 15, 2025, 3:29 AM EST - 7 weeks ago

Dividend Income: Lanny's October 2025 Summary

BNL BNS BRT CAH CM CSCO DEO

Dec 12, 2025, 4:42 PM EST - 7 weeks ago

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

Dec 12, 2025, 9:02 AM EST - 7 weeks ago

GSK gets EU regulator backing for expanded use of RSV vaccine

Dec 12, 2025, 8:58 AM EST - 7 weeks ago

European health regulator recommends approval for GSK's twice yearly asthma drug

Dec 11, 2025, 12:35 PM EST - 7 weeks ago

US FDA approves GSK's oral treatment for gonorrhea

Dec 10, 2025, 2:00 AM EST - 7 weeks ago

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Dec 5, 2025, 1:35 PM EST - 2 months ago

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

MRK SNY

Dec 1, 2025, 10:15 AM EST - 2 months ago

BREAKING: Trump strikes major deal with UK on drug pricing

AZN EWU EWUS FKU FLGB FXB

Nov 21, 2025, 8:52 AM EST - 2 months ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

ANAB

Nov 21, 2025, 8:48 AM EST - 2 months ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

ANAB

Nov 21, 2025, 6:14 AM EST - 2 months ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

ANAB

Nov 21, 2025, 3:50 AM EST - 2 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

ANAB

Nov 19, 2025, 11:23 AM EST - 2 months ago

GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD JNJ LLY

Nov 6, 2025, 6:23 AM EST - 3 months ago

GlaxoSmithKline India reports higher second-quarter profit on specialty medicine growth

Nov 4, 2025, 11:40 AM EST - 3 months ago

3 Dividend Stocks for November 2025

DEO KMB

Oct 29, 2025, 12:46 PM EDT - 3 months ago

GSK plc (GSK) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 9:08 AM EDT - 3 months ago

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

Oct 29, 2025, 4:08 AM EDT - 3 months ago

GSK Raises Guidance After Sales, Earnings Growth

Oct 29, 2025, 3:10 AM EDT - 3 months ago

GSK raises 2025 sales forecast after strong growth in specialty medicines

Oct 24, 2025, 7:24 AM EDT - 3 months ago

GSK shares fall as narrow approval of blood cancer drug limits US relaunch

Ro_Patel Feb. 3 at 10:44 PM

0 · Reply

Investor6 Jan. 30 at 4:21 PM

0 · Reply

JuggernautRaider Jan. 30 at 1:14 PM

0 · Reply

oceanviewhi Jan. 30 at 12:45 AM

1 · Reply

BillionerOfKing Jan. 29 at 6:18 PM

0 · Reply

Alex19949 Jan. 29 at 5:06 PM

$GSK Low volatility environment

0 · Reply

Stock_Savage Jan. 28 at 3:07 PM

$PFE Took my profits from $GSK and added to my $PFE position

0 · Reply

Coyote_7 Jan. 27 at 10:10 PM

0 · Reply

Justrise07 Jan. 27 at 6:34 PM

$GSK are you buying $CAMP therapudics , what’s going on ?

0 · Reply

taxplanr Jan. 25 at 9:55 PM

0 · Reply

SnapCrackleStop Jan. 23 at 3:18 PM

$SCYX Locked in. Overweight. $GSK has eyes 👀 on this one. Was a long wait but this is happening.. Huh? Yep. $$$

0 · Reply

Ravelodfg Jan. 23 at 12:49 PM

$GSK pharma large cap defensive grind with trend confirmation if healthcare bid sticks

0 · Reply

ZacksResearch Jan. 21 at 4:13 PM

$GSK making a bold pipeline move — is this the next growth catalyst? 🔥 GSK agreed to acquire RAPT Therapeutics for $2.2B, adding ozureprubart and strengthening its respiratory and immunology portfolio — a clear signal of where management is doubling down. See what this deal adds to the long-term story 👉 https://www.zacks.com/stock/news/2820494/gsk-to-boost-respiratory-immunology-pipeline-with-22b-rapt-buyout?cid=sm-stocktwits-2-2820494-teaser-29852&ADID=SYND_STOCKTWITS_TWEET_2_2820494_TEASER_29852

0 · Reply

ZacksResearch Jan. 21 at 3:13 PM

$GSK's acquisition of RAPT for $2.2B — a significant move for allergy treatments? 🤔 🌟 Adds ozureprubart, a promising IgE antibody in Phase IIb 💥 Strengthens GSK's respiratory, immunology, and inflammation pipeline Find out if this boosts GSK's market position 👉 https://www.zacks.com/stock/news/2820494/gsk-to-boost-respiratory-immunology-pipeline-with-22b-rapt-buyout?cid=sm-stocktwits-2-2820494-body-29851&ADID=SYND_STOCKTWITS_TWEET_2_2820494_BODY_29851

0 · Reply

Quantumup Jan. 21 at 2:17 PM

Bernstein⬆️ $BEAM's PT to $41 from $37 and reiterated at an Outperform rating. $TAK - $ARWR $WVE - $GSK Bernstein said in its note: We increase our PT to $41 following last week's positive regulatory update on the AATD program. Briefly, the company announced it has aligned with FDA on an accelerated approval pathway for BEAM-302. There are always questions about how "real" the alignment is for these sorts of things, but we believe based on discussions with mgmt that this is about as real as it can get. We think there is still a sizable gap between the current share price and fair value—we think it's at least conceivable that pharma majors might be interested now that FDA has provided greater clarity on the AATD regulatory path.

0 · Reply

ZacksResearch Jan. 20 at 7:32 PM

Is $GSK a better bet than $BMY right now? 🔍 GSK's diversified revenue base and strong HIV portfolio have driven a 42.8% gain over the past year, outpacing BMY's 3.1% decline. Plus, with promising new drug approvals and label expansions, GSK’s growth prospects look solid despite some pressure in its Vaccines segment. Discover why GSK might be the smarter choice currently 👉 https://www.zacks.com/stock/news/2819967/bmy-vs-gsk-which-biopharma-giant-has-better-prospects-for-now?cid=sm-stocktwits-2-2819967-body-29747&ADID=SYND_STOCKTWITS_TWEET_2_2819967_BODY_29747

0 · Reply

prismmarketview Jan. 20 at 6:50 PM

#GSK ($GSK ) Finalizes $2.2 Billion Acquisition of RAPT Therapeutics, Targeting Food Allergy Market https://prismmarketview.com/gsk-finalizes-2-2-billion-acquisition-of-rapt-therapeutics-targeting-food-allergy-market/

0 · Reply

ZacksResearch Jan. 20 at 6:32 PM

$BMY vs $GSK — which biopharma giant actually sets up better right now? 💊 The two stack up very differently on growth outlooks, debt levels, pipelines, and shareholder returns — making this far from a clear-cut stock-picking call. See how the risk/reward really compares 👉 https://www.zacks.com/stock/news/2819967/bmy-vs-gsk-which-biopharma-giant-has-better-prospects-for-now?cid=sm-stocktwits-2-2819967-teaser-29746&ADID=SYND_STOCKTWITS_TWEET_2_2819967_TEASER_29746

0 · Reply

TalkMarkets Jan. 20 at 5:48 PM

Why Is #RAPT Stock Skyrocketing Today? #GSK’s $2.X.2B Offer Drives Rally $GSK $RAPT https://talkmarkets.com/content/stocks--equities/why-is-rapt-stock-skyrocketing-today-gsks-22b-offer-drives-rally?post=551344

0 · Reply

DrizzleMesh Jan. 20 at 4:54 PM

$GSK largecap pharma steady accumulation defensive t

0 · Reply

AStrokeOfLuck Jan. 20 at 4:43 PM

$PFE $MRK $MRNA $SPY $GSK

0 · Reply

PhilipCallahan680 Jan. 20 at 4:31 PM

$GSK continues advancing pharmaceutical innovation across vaccines and specialty medicines. AITX discussed global demand signals and disciplined growth execution during its January 17 weekly update. https://aitx.ai/press-releases/steve-reinharz-breaks-down-q3-results-progress-global-demand-and-the-path-ahead

0 · Reply

Market Cap	105.18B
Revenue (ttm)	40.10B
Net Income (ttm)	3.29B
EPS (ttm)	N/A
PE Ratio	11.44
Forward PE	10.46
Profit Margin	8.21%
Debt to Equity Ratio	1.13

Volume	6,203,738
Avg Vol	4,244,396
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	96%
Beta	0.45
Analysts	Sell
Price Target	$47.42